Research and Markets: Erectile Dysfunction - Pipeline Review, H1 2013

<0> Research and Markets: Erectile Dysfunction - Pipeline Review, H1 2013 </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: , </0>

() has announced the addition of the report to their offering.

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.

- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Mentioned

- Acorda Therapeutics, Inc.

- Bayer AG

- Chong Kun Dang Pharmaceutical

- Dong-A Pharmaceutical Co., Ltd.

- Futura Medical plc.

- Global Health Ventures Inc.

- IntelGenx Technologies Corp.

- Medisyn Technologies, Inc.

- NexMed, Inc.

- Palatin Technologies, Inc.

- Quatrx Pharmaceutical Company

- Rexahn Pharmaceuticals, Inc.

- Sanofi-Aventis

- VIVUS, Inc.

- Vectura Group plc

- Yuhan Corporation

For more information visit

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.